Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed-Based Induction and Chemoradiotherapy in Recurrent HNC
NCT01172470Phase 2Completed
- Sponsor
- University of Chicago
- Start
- Jun 2005
- Primary completion
- Jun 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemetrexed in head and neck cancer (HNC), sponsored by University of Chicago. Primary endpoint: 1-year Survival Rate. Started Jun 2005; status: completed.
02
Drugs
pemetrexed
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on NCT01172470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01172470.